News for Roche Holding AG (RHHBY)

AstraZeneca Plc may sell some of its medicines directly to patients in the US, joining several other drugmakers that have plans to bypass middlemen or are considering them. “We are absolutely considering this,” Chief Executive Officer Pascal Soriot said on a call with reporters after reporting better-than-expected sales and rising profit, spurred by growth in the US.

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Key Highlights: Roche's gene therapy, Elevidys, faces hurdles in Europe due to a denied marketing application. Despite setbacks, analysts predict an 8.35

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Group Sales Growth: Increased by 7%.Pharmaceuticals Sales Growth: Increased by 10%, with Q2 growth at 11%.Diagnostics Sales: Flat due to China Healthcare prici

Jul 24, 2025 / 12:00PM GMTOperator On your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and

Key Takeaways: Roche (RHHBY) plans to engage directly with U.S. consumers, potentially reducing drug prices by 50%. Analysts forecast a moderate upside f

The major U.S. index futures are currently pointing to a higher open on Wednesday, with stocks likely to move to the upside after ending the previous session mixed.

European stocks were sharply higher on Wednesday after three straight sessions of losses. Focus shifted to potential trade agreements after U.S. President Donald Trump announced trade deals with Japan & Philippines.

Roche (RHHBY) proposes to exchange non-voting equity securities for participation certificates. Bearer shares' nominal value to be reduced from CHF 1.00

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a further transition to intermediated securities, in line with efficient and modern market practices. The exchange of Genussscheine for participation certificates and the reduction as well as the repayment of the nominal value of the bearer shares will be submitted to the shareholders for approval at the 2026 Annual General Meeting Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ('2026 AGM'). The proposal includes the exchange of the existing non-voting equity securities ('Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

Key Takeaways: Roche's Genentech unit's asthma drug trial did not meet primary objectives. Analysts forecast a potential 12.84% stock upside with a targe

The report gave a little bit of everything to Fed policymakers who are divided as to whether tariffs will cause a one-time price shock or something more persistent.

Global economic updates including US inflation, China GDP, and European job data, with insights on tariffs, interest rates, and more.

Summary: Genentech, part of Roche (RHHBY), faces FDA rejection for expanded use of Columvi. Analysts set a one-year target for Roche with a projected ups

Roche (RHHBY) announces the retirement of key executives, Dr. Hans Clevers and Barbara Schädler, scheduled for 2025. Dr. Hans Clevers will retire from

Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ETCompany ParticipantsBruno Eschli - Head of Investor...

Key Insights: Genentech's trial yields a 59% reduction in disease progression for lymphoma patients. Analysts forecast a potential 14.78% upside for Roch